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Abstract
Objective—The primary objective of this pilot study is to determine and compare the residence 
time in the vagina of biomarkers of semen exposure for up to 15 days post exposure. The 
biomarkers are prostate-specific antigen (PSA), Y chromosome DNA, the sex determining region 
of the Y chromosome (SRY) and testis-specific protein Y-encoded 4 (TSPY4). The secondary 
objectives are to determine if biomarker concentrations differed between intercourse and 
inoculation groups, to establish whether the sampling frequency post exposure affected biomarker 
concentrations and decay profile and to determine if biomarker concentrations in vaginal swabs 
obtained by the participant at home were similar to swabs obtained by the nurse in the clinic.
Study design—We randomized healthy women to unprotected intercourse (n=17) versus vaginal 
inoculation with the male partner’s semen in the clinic (n=16). Women were then further 
randomized to have vaginal swabs obtained at either 7 or 4 time points after semen exposure, up to 
15 days post exposure, either obtained at home by the participant or in the clinic by the research 
nurse.
Results—PSA and SRY were markers of recent semen exposure. TSPY4 was detectable in 
approximately 50% of participants at 15 days post exposure. Unprotected intercourse resulted in 
significantly higher concentrations of select biomarkers. Sampling frequency and home versus 
clinic sampling had no significant effect on biomarker concentrations.
Conclusions—Objective biomarkers of recent or distant semen exposure may have great utility 
for verifying protocol compliance in a variety of clinical trials.
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Objective biomarkers of vaginal exposure to semen were developed for use in forensic 
medicine to provide evidence of sexual contact [1]. Ultimately they may be used as 
surrogates for risk of pregnancy and sexually transmitted infections (STIs) and alternative 
endpoints in contraceptive efficacy trials [2–9], the assessment of slippage/breakage of 
condoms [7,8,10–14], and as an objective biomarker to validate self-reports of condom use 
and/or sexual activity [15–23].
Prostate-specific antigen (PSA) is the best characterized marker of seminal fluid (reviewed 
in Ref. [24]). PSA is detectable in the vagina immediately post exposure until approximately 
24–48 h post exposure [1,8,10,11,25,26]. Other objective biomarkers of sperm or male cell 
exposure are linked to Y chromosome DNA (YcDNA), present in Y-bearing spermatozoa, 
immature germ cells and nongerminal male cells (e.g., epithelial cells and leukocytes). Two 
genes on the Y chromosome that are of particular interest are the sex determining region of 
the Y chromosome (SRY) and the testis-specific protein Y-encoded 4 (TSPY4) gene [27–
29]. These biomarkers were utilized in small clinical trials, from the cell pellet from 
cervicovaginal lavage specimens [17] and vaginal swabs [5,17,26,30].
For new biomarkers to be used in future contraceptive and other clinical trials, it is important 
to determine residence time in the vagina under various exposure and sampling conditions. 
Only a few published studies were structured this way, with measurement of PSA and 
YcDNA as endpoints [8,10,11,26], and none compared methodologies to assess these new 
semen biomarkers.
The primary objective of this study is to describe the decay of SRY and TSPY4 in the 
vagina, for up to 15 days, using two different polymerase chain reaction (PCR) platforms, 
multiplex PCR and quantitative PCR (qPCR). Utilizing exposure to semen through 
unprotected vaginal intercourse or inoculation with the partner’s semen in the clinic, we 
measured and categorized biomarker detection post exposure and determined whether 
sampling frequency affects the decay of the markers. Finally, we compared concentrations of 
semen biomarkers obtained from vaginal swabs collected at home versus swabs obtained 
from the same participant by a research nurse in the clinic.
2. Materials and methods
This is a single-blinded, randomized, outpatient trial conducted at the Johns Hopkins 
University (JHU) Bayview Medical Center (Baltimore, MD) and the CONRAD Clinical 
Research Center (CRC) at the Eastern Virginia Medical School (EVMS) in Norfolk, VA. 
The institutional review board (IRB) (Approval Number NA_00016471) at the JHU (for the 
Bayview site) and the Chesapeake IRB (Protocol #Pro0003114) for the CONRAD CRC site 
approved this protocol. We screened monogamous couples at low risk of acquiring STIs, 
including a healthy, normally menstruating woman, aged 18–50 years, who was not at risk 
for pregnancy due to surgical sterilization or who was willing to become pregnant, and her 
male sexual partner, aged 18–55 years.
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Women and men were interviewed and consented separately. Men enrolled in the study had 
to be in good health and had to have screening semen sample parameters as follows: volume: 
≥1.8 mL (or ≥1.0 mL with a total sperm count of ≥120 million), total sperm count: 100–400 
million, sperm concentration: ≥35 M/mL, total sperm motility (progressive motility
+nonprogressive motility): ≥40%, viability: ≥70% vital cells, round cells: ≤5 M/mL and 
leukocytes: ≤1 M/mL.
We used the random permuted blocks method to generate allocation sequences assigning the 
couples to one of four subgroups (A1, A2, B1 and B2) in a 1:1:1:1 ratio. The sequences 
were created by a randomization manager, not otherwise involved in the statistical analyses 
of this study using a verified program based on the random function RANUNI in the SAS(r) 
System (SAS Institute, Cary, NC). The randomization groups and interventions are outlined 
in Table 1.
Women were given the choice of having all the vaginal swabs collected in the clinic by a 
nurse (“in-clinic sampling”) or having some samples collected in the clinic and collecting 
some at home (“mixed sampling”). For those opting for “mixed sampling”, all samples taken 
at 6 and 48 h were collected by the participant at home; a nurse in the clinic collected the 
remaining samples. Participants were instructed to abstain from vaginal or receptive oral 
intercourse during the 15 days of follow-up.
Up to two women in each of the four groups (A1, A2, B1 and B2) were invited to participate 
in a substudy. These women were asked to go through the study visits a second time, in their 
same group assignment, using the type of sampling that they did not use during their first 
time through to test the hypothesis that samples collected by participants yielded results 
similar to those collected in the clinic by the nursing staff.
Participants’ swabs were immediately placed in 1 mL of cold phosphate buffered saline 
(PBS). Next, the solution was spun for 5 min at 14,000 rpm. We sent the supernatant to the 
Centers for Disease Control and Prevention for PSA measurements, as previously described 
[31]. The pellet was resuspended in 700 μL PBS, and half was used for SRY qPCR (labeled 
“YcDNA”) analysis, and the other half was used for SRY-TSPY4 multiplex PCR and 
TSPY4 qPCR analysis, both performed as previously described [32,33].
We developed the TSPY4 qPCR using the Universal Probe Library system in combination 
with the Lightcycler TaqMan Master kit for the Lightcycler 2.0 (Roche Diagnostics, 
Indianapolis, IN). The method detected that TSPY4 amplified from sperm DNA as low as 1 
pg and, in semen samples with DNA, as low as 2 pg. We used both qPCR and multiplex 
PCR to assess both Y chromosome biomarkers to measure semen exposure. Although both 
assays detect the SRY region of the Y chromosome, we use the terms SRY for the multiplex 
system and YcDNA for the qPCR system, to maintain consistency with previously published 
data [26,32,33].
Statistical analyses were performed using SAS version 9.3 (Carey, NC). Descriptive 
statistics were expressed as mean, median and standard deviation. Independent group 
comparisons for normally distributed data were compared with parametric methods and for 
nonnormally distributed data with nonparametric methods, as appropriate. Paired 
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comparisons were performed to compare the quantity of biomarker detected on vaginal 
swabs obtained at home and in the clinic, from the same woman. Repeated-measures 
analysis was used to compare in clinic versus at home sampling among participants enrolled 
in the substudy. Statistical significance was detected at a p value of <.05.
3. Results
We screened 71 women and enrolled 33 couples (Table 1). Two women from the EVMS site 
withdrew from the main study. Only one woman (randomized to the B2 group) reported a 
protocol violation (unprotected intercourse) during the 15 days of follow-up. Usable swabs 
from the main study include the following: baseline (n=33), 6 h (n=33), 24 h (n=33), 48 h 
(n=15), 72 h (n=16), 7 days (n=32), 11 days (n=15) and 15 days (n=31). Nine women from 
the main study continued to the substudy and eight women provided at least one sample 
(Table 1). Usable swabs available for analysis from the substudy population include the 
following: baseline (n=8), 6 h (n=8), 24 h (n=8), 48 h (n=4), 72 h (n=4), 7 days (n=7), 11 
days (n=3) and 15 days (n=7).
There were no differences in demographic characteristics among participants randomized to 
inoculation (Group A) versus intercourse (Group B) (Table 2), nor were there differences in 
baseline semen parameters or in baseline vaginal levels of the four semen biomarkers based 
on randomization group (all p values >.05, data not shown).
The data support that the frequency of sampling post semen exposure (7 versus 4 samplings) 
had no effect on the mean vaginal concentrations of all semen biomarkers regardless of 
whether women were exposed via inoculation or unprotected intercourse (all p values >.05, 
data not shown). There was one exception to this. At the first sampling, 6 h, women 
randomized to A1 had significantly higher mean vaginal concentrations of TSPY4 
(9862±1158 ng/mL) compared to women randomized to A2 (TSPY4=7213±2372 ng/mL) 
(p=.02). This significant difference at 6 h was not seen in the timed intercourse group 
comparison (B1 versus B2).
At almost all time points, intercourse resulted in a trend toward higher mean concentrations 
of semen biomarkers than vaginal inoculation. These differences were significantly higher (p 
values <.05) at 6 and 24 h post exposure for various semen biomarkers (Supplemental Table 
1).
Comparing self-swabbing at home versus nurse collected swabs, we found no significant 
differences in the mean concentrations of any biomarker at any time point (all p values >.36, 
data not shown).
The residence time of the biomarkers, based on exposure groups, is detailed in Supplemental 
Table 1 and graphically in Fig. 1a–e. Using multiplex technology, SRY can be detected up to 
48 h, while TSPY4 can be detected up to 7 days. qPCR technology extended the window of 
detection of YcDNA and TSPY4.
To determine the proportion of all participants (n=41), in the main (n=33) and substudies 
(n=8) with detectable biomarker concentrations at each time point, we considered YcDNA, 
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SRY or TSPY4 concentrations of greater than 0.1 ng/mL and a PSA concentration of greater 
than 1.0 ng/mL as detectable, based on previous reports and the lowest limits of detection 
used in our assays [1,10,25,26]. This percentage is termed the actual detectable levels (Table 
3). We then reexamined the data and used levels of PSA as an internal control, to detect 
presumed unreported protocol violations. Given the consistent data that PSA is present in the 
female genital tract for approximately 24–48 h after semen exposure [8,10,11,25,26], we 
assumed that once the PSA level was undetectable for an individual participant, subsequent 
PSA levels of 1 ng/mL or higher indicated new, recent semen exposure or unreported 
protocol violations. The adjustments were used to calculate the percent of detectable 
biomarkers at each visit, adjusted for presumed protocol violations.
There were no adjustments made for presumed protocol violations for all time points up to 7 
days because no woman had detectable levels of PSA (>1 ng/mL) after levels initially fell to 
zero. The internal control of PSA was applied to samples obtained at the 11 and 15 day 
sampling times. At 11 days, one participant had a vaginal PSA level of 9.3 ng/mL, after 
having a vaginal PSA levels of ranging from 0.02 to 0.11 ng/mL between 48 h and 7 days. 
At 15 days, 7 women out of 38 participants had elevated levels of PSA (range 1.16–384 
ng/mL) after demonstrating undetectable PSA levels (<1 ng/mL) at day 7 and or day 11.
We found that the median vaginal concentration for all biomarkers was 0 ng/mL by 7 days 
post exposure. Table 3 demonstrates that SRY was a marker of recent intercourse (6–72 h), 
with the proportion of samples with detectable levels dropping to 0% by 72 h, while TSPY4 
detection, by multiplex PCR, extended the window of detection up to 7 days post semen 
exposure in 15% of participants. qPCR increased the sensitivity and window of detection for 
both SRY (YcDNA) and TSPY4 (Table 3). TSPY4, when assessed by qPCR, was the most 
robust biomarker, detectable in approximately 47.1–50.0% of participants at 11 and 15 days 
post semen exposure.
4. Discussion
We confirmed that the multiplex technology enables us to combine a marker of recent semen 
exposure (SRY) with a marker of longer-term exposure (TSPY4). qPCR technology 
extended the window of detection beyond 7 days. TSPY4, measured with qPCR technology, 
was the most robust marker. No other study has measured these semen biomarkers, by both 
technologies, at defined time points, after exposure to semen by intercourse or vaginal 
inoculation.
Intercourse resulted in higher concentrations of YcDNA, SRY and TSPY4 at various time 
points for up to 7 days post exposure compared to vaginal inoculation. This is consistent 
with previous studies showing that higher volumes of inoculated semen (up to 1 mL) 
resulted in more consistent decay profiles of vaginal PSA and YcDNA levels [26]. We 
investigated the effect of frequency of genital sampling on biomarker concentrations 
because, in a previous study, frequent sampling was shown to decrease the sensitivity of 
detecting semen biomarkers among women exposed to very small volumes of semen (10 and 
100 μL), which modeled volumes that might be encountered with a condom failure or 
preejaculate exposure [26]. We concluded that the number of sampling times after vaginal 
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inoculation with 2 mL of semen or timed intercourse did not result in significant differences 
in the concentrations of semen biomarkers for up to 15 days post exposure. This finding has 
applications to the design of future clinical trials utilizing these biomarkers.
Our study confirms a previous study showing similar PSA levels among women sampled in 
the clinic versus providing swabs collected at home and extends these findings to newer 
semen biomarkers [8].
Finally, we found that the median concentration of all biomarkers was 0 ng/mL by 7 days 
post exposure, which suggests that participants in future clinical trials will likely need to 
provide at least weekly samples. The sensitivity of detecting markers post exposure is 
reduced as sampling is obtained greater than 7 days post exposure.
We confirmed that PSA [1,8,10,11,25,26] and SRY (assessed by multiplex PCR) were 
markers of recent semen exposure, with median concentrations of both markers falling to 0 
ng/mL by 72 h post exposure. Multiplex PCR is beneficial because multiple genes may be 
assessed using a single aliquot of sample [32].
Our data support that SRY, assessed by multiplex PCR, extends the window of semen 
detection beyond that offered by the PSA measurement from 48 to 72 h. However, it is 
unknown whether SRY can be utilized in determining semen exposure from vasectomized 
men. Because PSA can be detected in semen from vasectomized men or men with low 
sperm counts [34] and can be assayed with a point-of-care test in the clinic, PSA will likely 
remain the semen biomarker of choice in detecting recent exposure to semen from this 
population.
In terms of assessing semen exposure beyond 72 h, qPCR technology improved the 
sensitivity of the biomarkers. Using qPCR to assess SRY (termed YcDNA) improves the 
sensitivity of detecting SRY past 7 days of exposure. TSPY4, assessed by multiplex PCR, 
was detectable in 15% of participants at 7 days post exposure and was virtually undetectable 
by 11 and 15 days post exposure. qPCR markedly improved the sensitivity of TSPY4, being 
the most robust marker, detectable in 47.1–50.0% of participants at 15 days post exposure.
The sensitivities and concentrations that we report in this study are consistent with other 
studies, utilizing inoculation or timed intercourse, assessing YcDNA [16,17,26,30]. The 
half-life of YcDNA is estimated to be 3.6 days [16,17,26] and a previous clinical study 
reported that YcDNA was absent by 15 days post exposure [17]. Strengths of this study 
include the ability to compare biomarker concentrations after timed intercourse versus 
vaginal inoculation, the number of sampling times post exposure, home versus in clinic 
sampling and the addition of SRY and TSPY4, assessed by both multiplex and qPCR 
technologies.
This pilot study has several limitations. We did not include an arm of the study without 
semen exposure, so we cannot calculate specificity. Although only one woman reported a 
protocol violation at her follow-up visit, PSA levels indicate that at least eight unreported 
protocol violations occurred. Gaps of 4 days or more existed between some of the samplings 
(72 h, 7 days, 11 days and 15 days). Since PSA disappears by 24–48 h post exposure, it is 
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possible that there were additional unreported protocol violations. However, the mean and 
median levels of TSPY4 and SRY steadily declined after 11 days, supporting protocol 
adherence and our rationale for the adjusted analysis. Future studies, with more frequent 
(such as daily) sampling, are needed to further define the daily decay curves of these new 
biomarkers of semen exposure.
This was a pilot study to plot the decay of these biomarkers, based on exposure, sampling 
frequency and assessment method. Generalized mixed linear models controlling for within-
subject correlation of measurements and potential between-subject variation in the rate of 
signal decay would likely have increased the statistical power of the comparisons and the 
precision of the estimates. However, the sample size was too small, with individual cell sizes 
ranging from 3 to 9 individuals. The small sample size often leads to failures of convergence 
and other modeling problems, as well as interpretational difficulties from the effect of a few 
influential observations.
In summary, there is an interest in developing biologic markers of semen exposure as reports 
of condom use and other sexual behaviors in clinical trials are fraught with recall, social 
desirability and reporting biases. Our data demonstrate that PSA and SRY via multiplex 
PCR are markers of recent (up to 72 h) semen exposure, while qPCR assessment of TSPY4 
and SRY (YcDNA) are markers of semen exposure in the past 7–15 days. TSPY4 assessed 
by qPCR was the most sensitive long-term marker of semen exposure. It would be ideal to 
increase the sensitivity of detecting these biomarkers beyond 7 days, as women in clinical 
trials may be seen less frequently for follow-up. Our goal is to improve the sensitivity of the 
TSPY4 qPCR to detect semen exposure in nearly 100% of cases at 15 days. However, since 
menses, use of tampons or other intravaginal products, discharge and sex could all act to 
remove DNA, self-swabbing at home at weekly intervals may be the most feasible approach 
to detecting evidence of semen exposure. It is important to develop and characterize 
objective measures of product adherence and protocol compliance. Because women’s health 
trials often involve tracking intercourse or condom use, biomarkers of vaginal semen 
exposure will further the rational interpretation of data from these types of trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Decay Curves for Semen Biomakers, Based on Vaginal Inoculation (Groups A1 and A2) 
versus Intercourse (Groups B1 and B2) YcDNA (SRY by qPCR). (b) Decay Curves for 
Semen Biomakers, Based on Vaginal Inoculation (Groups A1 and A2) versus Intercourse 
(Groups B1 and B2) SRY by Multiplex PCR. (c) Decay Curves for Semen Biomakers, 
Based on Vaginal Inoculation (Groups A1 and A2) versus Intercourse (Groups B1 and B2) 
TSPY4 by Multiplex PCR. (d) Decay Curves for Semen Biomakers, Based on Vaginal 
Inoculation (Groups A1 and A2) versus Intercourse (Groups B1 and B2) TSPY4 by 
Multiplex PCR. (e) Decay Curves for Semen Biomarkers, Based on Vaginal Inoculation 
(Groups A1 and A2) versus Intercourse (Groups B1 and B2) TSPY4 by qPCR (Mean 
Values, ng/mL), Main Study, Treated Population.
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Table 1
Randomization Groups and Interventions in Semen Biomarkers Study
Semen Exposure Group
A B




A1 (7 Time Points) A2 (4 Time Points) B1 (7 Time Points) B2 (4 Time Points)
 (n=8)  (n=8)  (n=8)  (n=9)
 Clinic Sampling=4  Clinic Sampling=4  Clinic Sampling=5  Clinic Sampling=3
 Home Sampling=4  Home Sampling=4  Home Sampling=3  Home Sampling=6
A1 Substudy A2 Substudy B1 Substudy B2 Substudy
 (n=3)  (n=2)  (n=2)  (n=2)
 Clinic Sampling=1  Clinic Sampling=0  Clinic Sampling=0  Clinic Sampling=0
 Home Sampling=2  Home Sampling=2  Home Sampling=2  Home Sampling=2
The A1 and B1 groups underwent vaginal sampling for biomarkers of semen exposure at 7 time points after inoculation or intercourse (6 h, 24 h, 48 
h, 72 h, 7 days, 11 days and 15 days post exposure).
The A2 and B2 underwent vaginal sampling for biomarkers of semen exposure at 4 time points after inoculation or intercourse (6 h, 24 h, 7 days 
and 15 days post exposure).
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Table 3
Percent of Participants with Detectable Levels of Biomarkersa, Adjusted for Presumed Protocol Violations, All 
Main and Substudy Participants, at Each Time Point
Variable Proportion of Participants with Detectable Levels of Biomarkers in Main and Substudies (Actual Percent and 
Adjusted Percent for Presumed Protocol Violations, Using PSA as an Internal Control)
Actual % Detected Adjusted for Presumed Protocol Violations % 
Detected
6 h
 YcDNA (SRY qPCR) 97.6 97.6
 SRY (Multiplex) 90.0 90.0
 TSPY4 (Multiplex) 100 100
 TSPY4 (qPCR) 100 100
 PSA 100 100
24 h
 YcDNA (SRY qPCR) 95.2 95.2
 SRY (Multiplex) 50.0 50.0
 TSPY4 (Multiplex) 95.0 95.0
 TSPY4 (qPCR) 100 100
 PSA 69.0 69.0
48 h
 YcDNA (SRY qPCR) 89.5 89.5
 SRY (Multiplex) 16.7 16.7
 TSPY4 (Multiplex) 77.8 77.8
 TSPY4 (qPCR) 88.9 88.9
 PSA 16.7 16.7
72 h
 YcDNA (SRY qPCR) 80.0 80.0
 SRY (Multiplex) 0 0
 TSPY4 (Multiplex) 57.9 57.9
 TSPY4 (qPCR) 78.9 78.9
 PSA 10.0 10.0
7 days
 YcDNA (SRY qPCR) 38.5 38.5
 SRY (Multiplex) 0 0
 TSPY4 (Multiplex) 15.4 15.4
 TSPY4 (qPCR) 64.1 64.1
 PSA 0 0
11 days
 YcDNA (SRY qPCR) 16.7 17.6
 SRY (Multiplex) 0 0
 TSPY4 (Multiplex) 0 0
 TSPY4 (qPCR) 50.0 47.1
 PSA 5.5a 0
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Variable Proportion of Participants with Detectable Levels of Biomarkers in Main and Substudies (Actual Percent and 
Adjusted Percent for Presumed Protocol Violations, Using PSA as an Internal Control)
Actual % Detected Adjusted for Presumed Protocol Violations % 
Detected
15 days
 YcDNA (SRY qPCR) 18.4 16.1
 SRY (Multiplex) 5.3 0
 TSPY4 (Multiplex) 13.5 10.0
 TSPY4 (qPCR) 50.0 48.4
 PSA 18.4b 0
a
One participant (out of 18) had an elevated PSA at 11 days after having undetectable PSA levels at 7 days and is therefore removed for the 
adjusted analysis for a suspected protocol violation.
b
Of 38 participants, 7 had an elevated PSA at 15 days after having undetectable PSA levels at 7 or 11 days and are therefore removed for the 
adjusted analysis for suspected protocol violations.
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